It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Activation of microglia is a prominent pathological feature in tauopathies, including Alzheimer’s disease. How microglia activation contributes to tau toxicity remains largely unknown. Here we show that nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling, activated by tau, drives microglial-mediated tau propagation and toxicity. Constitutive activation of microglial NF-κB exacerbated, while inactivation diminished, tau seeding and spreading in young PS19 mice. Inhibition of NF-κB activation enhanced the retention while reduced the release of internalized pathogenic tau fibrils from primary microglia and rescued microglial autophagy deficits. Inhibition of microglial NF-κB in aged PS19 mice rescued tau-mediated learning and memory deficits, restored overall transcriptomic changes while increasing neuronal tau inclusions. Single cell RNA-seq revealed that tau-associated disease states in microglia were diminished by NF-κB inactivation and further transformed by constitutive NF-κB activation. Our study establishes a role for microglial NF-κB signaling in mediating tau spreading and toxicity in tauopathy.
Wang et al show that microglial NF-κB activation is essential for tau spreading and tau-mediated spatial learning and memory deficits in tauopathy mice. Inactivation of NF-κB reversed tau associated microglial states and rescued autophagy deficits.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Li, Fan 2 ; Khawaja, Rabia R 3 ; Liu, Bangyan 2 ; Zhan Lihong 1 ; Kodama Lay 2
; Chin, Marcus 1
; Li, Yaqiao 1 ; Le, David 1 ; Zhou Yungui 1 ; Condello Carlo 4
; Grinberg, Lea T 5
; Seeley, William W 5 ; Miller, Bruce L 5 ; Mok Sue-Ann 6
; Gestwicki, Jason E 7
; Cuervo, Ana Maria 3
; Luo Wenjie 2
; Gan, Li 8
1 University of California, San Francisco, Gladstone Institutes, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
2 Brain and Mind Research Institute, Weill Cornell Medicine, Helen and Robert Appel Alzheimer’s Disease Institute, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X)
3 Albert Einstein College of Medicine, Department of Developmental and Molecular Biology, Bronx, USA (GRID:grid.251993.5) (ISNI:0000000121791997)
4 University of California, San Francisco, Institute for Neurodegenerative Diseases, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); University of California, San Francisco, Department of Neurology, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
5 University of California, San Francisco, Department of Neurology, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); University of California, San Francisco, Memory and Aging Center, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
6 Faculty of Medicine and Dentistry, University of Alberta, Department of Biochemistry, Edmonton, Canada (GRID:grid.17089.37) (ISNI:0000 0001 2190 316X)
7 University of California, San Francisco, Institute for Neurodegenerative Diseases, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); University of California, San Francisco, Department of Pharmaceutical Chemistry, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
8 University of California, San Francisco, Gladstone Institutes, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); Brain and Mind Research Institute, Weill Cornell Medicine, Helen and Robert Appel Alzheimer’s Disease Institute, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X)




